Target Product Profile For A Gambiense Human African Trypanosomiasis Test To Identify Individuals To Receive Widened Treatment
Download Target Product Profile For A Gambiense Human African Trypanosomiasis Test To Identify Individuals To Receive Widened Treatment full books in PDF, epub, and Kindle. Read online free Target Product Profile For A Gambiense Human African Trypanosomiasis Test To Identify Individuals To Receive Widened Treatment ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : |
Publisher | : World Health Organization |
Total Pages | : 14 |
Release | : 2022-03-23 |
Genre | : Medical |
ISBN | : 9240043292 |
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 14 |
Release | : 2022-12-15 |
Genre | : Medical |
ISBN | : 9240064192 |
The WHO Department of Control of Neglected Tropical Diseases (NTD) manages a diverse portfolio of twenty diseases, each with its own unique challenges, including the diagnostic aspect. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was formed, and a specific subgroup was created to advise on the human African trypanosomiasis (HAT) diagnostic innovation needs. The purpose of this TPP is to communicate the minimum and ideal characteristics desired to meet the need for a simpler and more performant test able to confirm an infection with Trypanosoma brucei gambiense, usable by non-specialised personnel in the context of disease elimination. The primary target audience is the potential developers of diagnostic tests and the potential donors that could provide funding for this tools that are considered priorities by the experts convened by WHO.
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 111 |
Release | : 2024-05-03 |
Genre | : Medical |
ISBN | : 9240091238 |
Concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypanosomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on Neglected tropical diseases, adopted in 2013. National sleeping sickness control programmes (NSSCPs) are core to progressing in the control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for these achievements. More than 20 years of partnership among WHO, Sanofi and Bayer have enabled WHO to strengthen and sustain financial, technical and material support for the implementation of control activities in countries where HAT is endemic. The long-term support from the Government of Belgium, the Bill & Melinda Gates Foundation (BMGF) and other research institutions in the Democratic Republic of the Congo (DRC) has also been essential. WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandemic and jointly for both forms of the disease. The previous meetings on g-HAT held in 2014, 2016 and 2018, as well as on r-HAT in 2015, 2017 and 2019, and jointly for g-HAT and r-HAT in 2021 (8) reinforced the partnership and commitment for HAT elimination and structured the mechanisms of collaboration within the WHO network for HAT elimination. The network includes NSSCPs, groups developing new tools, international and nongovernmental organizations involved in disease control, and donors. Fewer than 1000 cases of HAT annually have been reported over the past 5 years, which is a historic achievement. The area at risk has been substantially reduced. The elimination of HAT as a public health problem at the global level has been achieved. The new road map for neglected tropical diseases (NTDs) 2021−2030 (“the road map”) with the target to interrupt the transmission of g-HAT requires the strengthened and sustained efforts of all stakeholders, national authorities and partners, under WHO coordination. It will take disproportionally high efforts and innovative strategies to find the last cases of g-HAT and neutralize its transmission. Given the limited resources and other competing public health priorities, this is a challenge that requires our joint commitment.
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 86 |
Release | : 2024-05-04 |
Genre | : Medical |
ISBN | : 924009153X |
This document is the second in a series of global reports describing progress towards the 2030 targets set in Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. It describes a wide range of activities, accomplishments and challenges across the portfolio of NTDs and across all six WHO regions. The report presents epidemiological and programmatic data for 2022, which were gathered, compiled and analysed in 2023. In some cases, 2023 data are available and presented; in other cases, less recent information is included, when 2022 data are not available. In addition, it presents the main facts or events that occurred in 2023. In line with the road map’s companion document Ending the neglect to attain the Sustainable Development Goals: a framework for monitoring and evaluating progress of the road map for neglected tropical diseases 2021−2030, the report includes quantitative information on the status of the overarching, cross-cutting and disease-specific indicators. This is followed by qualitative information on each of the three road map pillars and on regional and country progress. The conclusions of the report and way forward are further complemented by annexes on cross-cutting indicator 6, status of donated medicines for treatment of NTDs, articles on NTDs published in the Weekly Epidemiological Record, target product profiles published as of 31 December 2023 and the list of global NTD reports published by WHO so far.
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 82 |
Release | : 2023-01-30 |
Genre | : Medical |
ISBN | : 9240067299 |
The Global report on neglected tropical diseases 2023 provides a consolidated, up-to-date assessment of progress towards control, elimination and eradication of 20 diseases and disease groups (NTDs) globally, regionally and nationally. Progress is reported in the context of global commitments, strategies and targets set in the NTD road map 2021-2030. The document covers the first two years of implementation of the road map (2021 and 2022). The information presented is based primarily on epidemiological and programmatic data for interventions conducted in 2021 and gathered in 2022, but the report also describes a wide range of activities and accomplishments that were registered in both 2021 and 2022; comparisons are often made against 2020 and 2019 data, especially with regard to COVID-19 disruptions. It has four sections: Section 1 is an introduction. Section 2 presents the status of the global NTD response. Section 3 charts progress and developments against the three road map pillars. Section 4 sets out priority actions for 2023 and beyond to sustain implementation of the road map and its companion documents. Five annexes to the report provide information for 2021–2022 on regional progress (Annex 1), Weekly Epidemiology Record articles on NTDs (Annex 2), progress and challenges by disease (Annex 3), diagnostic target product profiles (Annex 4) and the status of commitments for donated medicines and health products (Annex 5).
Author | : |
Publisher | : World Health Organization |
Total Pages | : 90 |
Release | : 2022-06-06 |
Genre | : Medical |
ISBN | : 924004504X |
Author | : |
Publisher | : World Health Organization |
Total Pages | : 40 |
Release | : 2022-04-27 |
Genre | : Medical |
ISBN | : 9240048065 |
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 36 |
Release | : 2024-06-30 |
Genre | : Medical |
ISBN | : 9240094784 |
The Diagnostic Technical Advisory Group (DTAG) for the WHO Global NTD Programme was formed to foster a unified approach for identifying and prioritizing diagnostic needs, and to inform WHO strategies and guidance on NTD diagnostics. The first meeting of the DTAG was held at the Inter Parliamentary Union in Geneva, Switzerland, in October 2019. The second took place virtually in October 2020, the third in June 2021, the fourth in October 2021 and the fifth in November 2022. Several disease-specific and cross-cutting DTAG subgroups have been formed, resulting in the development of target product profiles (TPPs) for new diagnostics, some of which have been published, and some of which are in production. WHO/NTD convened the sixth DTAG meeting on 14 and 15 February 2024, with the following objectives across the end-to-end process of diagnostic development: -consider updates from disease-specific subgroups and TPP production; -discuss progress made by the cross-cutting and resource mobilization subgroups; -discuss the Expert Review Panel for Diagnostics (ERPD) NTD pilot project and lessons learnt; -discuss engagement of manufacturers and developers; -discuss laboratory capacity strengthening and standardization of molecular methods; -deliberate on the priority/focus areas of engagement for the DTAG for the next 2 years.
Author | : World Health Organization |
Publisher | : World Health Organization |
Total Pages | : 211 |
Release | : 2015-08-05 |
Genre | : Medical |
ISBN | : 9241564865 |
"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.
Author | : Luis Rivas |
Publisher | : Royal Society of Chemistry |
Total Pages | : 422 |
Release | : 2017-10-26 |
Genre | : Science |
ISBN | : 1788012585 |
For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides. Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania. Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.